Labcorp (LH) EVP Brian Caveney sells 1,500 shares in open trade

Rhea-AI Filing Summary

LABCORP HOLDINGS INC. executive Brian J. Caveney, EVP and President of Enterprise Diagnostics, Chief Medical Officer and Chief Scientific Officer, reported an open-market sale of common stock. On February 24, 2026, he sold 1,500 shares at an average price of $286.305 per share.

After this transaction, Caveney directly owns 30,106.9234 shares of Labcorp common stock. This filing reflects an insider reducing his direct shareholdings through a routine open-market sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Caveney Brian J

(Last) (First) (Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON NC 27215

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Pres of ED, CMO & CSO

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		S		1,500	D	$286.305	30,106.9234	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Kathryn W. Kyle, Attorney-in-Fact for Brian J. Caveney	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Labcorp (LH) executive Brian J. Caveney report?

Brian J. Caveney reported a direct open-market sale of Labcorp common stock. On February 24, 2026, he sold 1,500 shares, reflecting a routine insider disposition rather than a purchase, and updated his remaining direct shareholdings in the company accordingly.

How many Labcorp (LH) shares did Brian J. Caveney sell and at what price?

Brian J. Caveney sold 1,500 shares of Labcorp common stock in an open-market transaction. The reported average sale price was $286.305 per share, providing a clear view of the transaction size and pricing disclosed in the insider filing for investors tracking executive trading.

How many Labcorp (LH) shares does Brian J. Caveney own after this sale?

After selling 1,500 shares, Brian J. Caveney directly owns 30,106.9234 Labcorp common shares. This figure represents his remaining direct holdings as reported in the filing and helps investors understand his ongoing equity exposure to the company following the disclosed sale.

What is Brian J. Caveney’s role at Labcorp (LH) in this insider sale filing?

Brian J. Caveney is identified as Labcorp’s Executive Vice President, President of Enterprise Diagnostics, Chief Medical Officer, and Chief Scientific Officer. His senior leadership position makes his equity transactions notable for investors monitoring insider activity and management’s direct ownership in the company.

Was Brian J. Caveney’s Labcorp (LH) transaction a buy or a sell?

The transaction was a sell. The filing classifies it as an open-market sale of 1,500 Labcorp common shares, using a sale transaction code and direction, indicating a reduction in his direct holdings rather than an acquisition or option exercise during the reported trade.